Bharat Biotech donates 2,00,000 Covaxin doses to Vietnam
Hyderabad: The Republic of Vietnam will receive two lakh doses of Bharat Biotech’s Covaxin. This donation represents a goodwill gesture to provide access to the company’s WHO approved, indigenously developed Covaxin to fight the Covid-19 pandemic across borders. Covaxin has received emergency use listing in Vietnam. Suchitra Ella, joint managing director of Bharat Biotech, revealed this at […]
Hyderabad: The Republic of Vietnam will receive two lakh doses of Bharat Biotech’s Covaxin. This donation represents a goodwill gesture to provide access to the company’s WHO approved, indigenously developed Covaxin to fight the Covid-19 pandemic across borders. Covaxin has received emergency use listing in Vietnam.
Suchitra Ella, joint managing director of Bharat Biotech, revealed this at an event hosted by Vuong Dinh Hue, president of the National Assembly of the Socialist Republic of Vietnam in the presence of several officials in New Delhi on Thursday.
Bharat Biotech was invited by the Embassy of Vietnam for a one-on-one meeting with the president of the National Assembly, to discuss avenues of cooperation, supplies, and technology transfer possibilities.
Suchitra Ella, joint managing director of Bharat Biotech, said the company wishes Covaxin contribution will help boost up the country’s national vaccination programme and recovery from the pandemic.
“We believe in vaccine equity, global public health, and having access to the vaccine is vital for national health, and I hope everyone in the Republic of Vietnam will take advantage of having access to the widely administered, safe and efficacious Covaxin,” said Dr Krishna Ella, CMD of Bharat Biotech.
In Vietnam, Bharat Biotech has been working with Duc Minh Medical Joint Stock Company, towards the commercialisation of Indirab (inactivated rabies vaccine). Duc Minh is Bharat Biotech’s local partner in Vietnam and the Hyderabad firm has earlier supplied Indirab to Vietnam supporting the nation’s rabies vaccine requirement.
Bharat Biotech has completed phase-2 and phase-3 trials of Covaxin for children in the age group 2 to 18 years. The data has been submitted to the Central Drugs Standard Control Organisation (CDSCO) and the final approval is awaited. On approval, children will also have access to Covaxin.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
